Cipla submits application with USFDA for generic version of GSK's Advair Diskus asthma drug
The company has submitted an abbreviated new drug application (ANDA) for Fluticasone propionate and Salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) to the US Food and Drug Administration (USFDA), Cipla said in a regulatory filing.
Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, Photo: Reuters